Biomarkers of ADHD Treatment Response

Launched by BOSTON CHILDREN'S HOSPITAL · Dec 6, 2022

Keywords

ClinConnect Summary

This clinical trial, called "Biomarkers of ADHD Treatment Response," is studying how brain activity can help predict how well children with ADHD will respond to two common medications: Concerta (methylphenidate) and Adderall (mixed amphetamine salts). The researchers want to find out if children who improve with Concerta have different brain patterns compared to those who don’t respond well. They will also look to see if children do better on Adderall have distinct brain signatures when compared to their responses to Concerta.

To participate, children aged 7 to 11 who have been diagnosed with ADHD and have not yet tried stimulant medications may be eligible. During the study, children will have their brain activity measured before starting either medication and again after a three-week trial period. Families will also share information each week about the child's symptoms and any side effects they may experience. This study will help provide a better understanding of how to tailor ADHD treatments based on individual responses, making it easier for doctors to find the right medication for each child.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pediatric patients ages 7-11 seen at the Children's Hospital Primary Care Center
• • Have a diagnosis of ADHD or referred for an ADHD evaluation
• • Have not previously trialed stimulant medication
• Exclusion Criteria:
• • Diagnoses of intellectual disability, autism, prior suicide attempt, current psychotropic medication use, known genetic syndrome, color-blindness
• • History of nonfebrile seizures
• • Gestational age \< 32 weeks
• • Prenatal alcohol or substance exposure
• • Medical conditions that contraindicate psychostimulant use (e.g., cardiac concerns).

Trial Officials